Advertisement

Topics

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma

10:00 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Opinion based on positive Phase 3 ALCANZA study results which demonstrated a highly statistically significant improvement in rate of objective response lasting at least four months, median progression-free survival and overa...

Other Sources for this Article

Takeda:
Japanese Media
Tsuyoshi Tada, +81 (0) 3-3278-2417
tsuyoshi.tada@takeda.com
or
European Media
Kate Burd,  +41 79 514 9533
kate.burd@takeda.com
or
Media outside Japan/EU
Sara Noonan, +1 617-551-3683
sara.noonan@takeda.com

NEXT ARTICLE

More From BioPortfolio on "Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...